| Old Articles: <Older 6321-6330 Newer> |
|---|
 |
The Motley Fool
May 11, 2010
Brian Orelli |
Swine Viruses Strike Again In March, the FDA recommended that doctors stop using GlaxoSmithKline's Rotarix, but still hasn't made a final decision on the drug.   |
The Motley Fool
May 8, 2010 |
Sequenom Restarting Development of Diagnostic Test for Down Syndrome The latest news at the San Diego-based biotech. |
The Motley Fool
May 7, 2010
Ryan McBride |
Athenahealth Paying Dearly to Take on Larger Rivals Athena has been ramping up efforts to raise its profile among doctors, the target audience for its Internet-enabled billing and electronic health records services. Yet the company has been criticized for the relatively high price of the push. |
The Motley Fool
May 7, 2010
Brian Orelli |
Drug Companies: Recession-Resistant, but Government-Proof? Greece decided to take action and forced drugmakers to reduce drug costs by an average of 21.5%. Investors need to think twice before making the seemingly sure bet on pharmaceutical companies. |
BusinessWeek
May 6, 2010
David Olmos |
Data Mining Helps Hospitals Pry Fees from Patients Billing software companies are helping hospitals identify patients with enough assets to cover their bills but who may need help figuring out to do it. |
The Motley Fool
May 6, 2010
Brian Orelli |
Johnson & Johnson, What Have You Done? We're not sure, but Congress wants to find out. The House Committee on Oversight and Government Reform launched an investigation yesterday into the recall JNJ announced last week. |
The Motley Fool
May 6, 2010
Brian Orelli |
Good Deal Now, Bad Deal Later: It's a Biotech Thing Ariad grabs cash now, but gives up long-term sales profits. |
InternetNews
May 5, 2010 |
Thousands of Kentucky Medical Records Lost A flash drive storing patient names, birth dates, admission and discharge dates, as well as insurance information has gone missing from a Kentucky psychiatric hospital. |
The Motley Fool
May 5, 2010
Brian Orelli |
Teva's Double-Edged Sword Nice quarter, but where will future growth come from? |
The Motley Fool
May 5, 2010
Brian Orelli |
Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is. |
| <Older 6321-6330 Newer> Return to current articles. |
